Announced Thu, 26 Mar · 15:09 IST

Intimation of Closure of Trading Window for the 4th Quarter and Annual Year Ended 31 March, 2026

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-7.7%1-day move
₹0.26
prior close
₹0.26
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0-3.8+0.0+0.0-7.7-3.8-3.8+0.0+3.8+19.2+26.9+15.4+15.4+0.0
Up moveDown movePending
AI summary

Welcure Drugs & Pharmaceuticals has informed BSE that its trading window will remain closed from April 01, 2026 until 48 hours after the declaration of audited standalone financial results for Q4 and the full financial year ended March 31, 2026. The closure applies to all Designated Persons, Designated Employees, Specified Persons, and their immediate relatives, as required under SEBI's Insider Trading Regulations, 2015 and the company's internal code of conduct. The intimation was signed by Managing Director Chintan Didawala Ganpat on March 26, 2026.

Likely market impact

This is a routine regulatory compliance filing with no direct impact on shareholders or stock price. It simply prevents insiders from trading ahead of the upcoming Q4 and annual results announcement, signaling that the company's audited financial results will be released sometime after April 1, 2026.